Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Hypertension does not directly cause dyspnoea; however it can lead to long-term effects on the heart and arteries ...

The management of pulmonary hypertension has already incorporated ... act principally through vasodilatation of the pulmonary arterial circulation through well-delineated mechanisms, although ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

Objectives: To determine the effect of vasopressin therapy on the efficacy of oxygenation and arterial pressure in infants with severe persistent pulmonary hypertension of the newborn. Conclusions ...